Format

Send to

Choose Destination
Haematologica. 2019 Aug 14. pii: haematol.2019.225375. doi: 10.3324/haematol.2019.225375. [Epub ahead of print]

Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma.

Author information

1
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX; eli.manasanch@gmail.com.
2
Karyopharm Therapeutics, Newton, MA.
3
Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
4
Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
5
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.
6
Lymphoma/Myeloma;Experimental Therapeutics,The University of Texas MD Anderson Cancer Center,Houston.

KEYWORDS:

Multiple Myeloma; carfilzomib; panobinostat; refractory; relapsed

PMID:
31413094
DOI:
10.3324/haematol.2019.225375
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center